ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.Frontiers in immunology · 2023Article
- P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.BMC cancer · 2015Article
- Novel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data.OncoTargets and therapy · 2015Article
- A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.Leukemia · 2014Article
- Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.Oncology (Williston Park, N.Y.) · 2014Review
- Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2013Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Gene expression profiling has been used to divide diffuse large B-cell lymphoma into distinct molecular subtypes with different outcomes following immunochemotherapy. Recently, researchers have shown much interest in investigating the role of biomarkers, such as BCL2, in predicting outcome in diffuse large B-cell lymphoma, particularly in the context of these molecular subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.